These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

559 related items for PubMed ID: 18950459

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X, Hans CP, Greiner TC, Bierman PJ, Bociek RG, Armitage JO, Chan WC, Vose JM.
    J Clin Oncol; 2008 Oct 01; 26(28):4587-94. PubMed ID: 18662967
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
    Martín A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, García-Sanchez P, Vázquez L, Nistal S, Requena MJ, Donato EM, González JA, León A, Ruiz C, Grande C, González-Barca E, Caballero MD, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO Cooperative Group).
    Haematologica; 2008 Dec 01; 93(12):1829-36. PubMed ID: 18945747
    [Abstract] [Full Text] [Related]

  • 7. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
    Natkunam Y, Farinha P, Hsi ED, Hans CP, Tibshirani R, Sehn LH, Connors JM, Gratzinger D, Rosado M, Zhao S, Pohlman B, Wongchaowart N, Bast M, Avigdor A, Schiby G, Nagler A, Byrne GE, Levy R, Gascoyne RD, Lossos IS.
    J Clin Oncol; 2008 Jan 20; 26(3):447-54. PubMed ID: 18086797
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma.
    Hyo R, Tomita N, Takeuchi K, Aoshima T, Fujita A, Kuwabara H, Hashimoto C, Takemura S, Taguchi J, Sakai R, Fujita H, Fujisawa S, Ogawa K, Motomura S, Suzuki R, Ishigatsubo Y.
    Hematol Oncol; 2010 Mar 20; 28(1):27-32. PubMed ID: 19358143
    [Abstract] [Full Text] [Related]

  • 16. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte.
    Bachy E, Brice P, Delarue R, Brousse N, Haioun C, Le Gouill S, Delmer A, Bordessoule D, Tilly H, Corront B, Allard C, Foussard C, Bosly A, Coiffier B, Gisselbrecht C, Solal-Celigny P, Salles G.
    J Clin Oncol; 2010 Feb 10; 28(5):822-9. PubMed ID: 20026809
    [Abstract] [Full Text] [Related]

  • 17. Improved survival for patients with large B-cell lymphoma after introduction of rituximab.
    Rodenburg EM, Maartense E, Posthuma EF.
    Neth J Med; 2009 Sep 10; 67(8):355-8. PubMed ID: 19767667
    [Abstract] [Full Text] [Related]

  • 18. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
    Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, Taji H, Kagami Y, Morishima Y.
    Eur J Haematol; 2008 Dec 10; 81(6):448-53. PubMed ID: 18691256
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.
    Kasteng F, Erlanson M, Hagberg H, Kimby E, Relander T, Lundkvist J.
    Acta Oncol; 2008 Dec 10; 47(6):1029-36. PubMed ID: 18607857
    [Abstract] [Full Text] [Related]

  • 20. New treatment options have changed the survival of patients with follicular lymphoma.
    Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP.
    J Clin Oncol; 2005 Nov 20; 23(33):8447-52. PubMed ID: 16230674
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.